A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: Advantages of pathway-based discovery

Marc Hellerstein

doi:10.1016/j.ymben.2007.09.003

Back

A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: Advantages of pathway-based discovery

Article 2007 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2025

Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway

Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, Kazuko Sakai, Naoto Fujiwara, Masakatsu Tsurusaki, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Atsushi Takebe, Takaaki Murase, Keiko Kamei, Takuya Nakai, Ippei Matsumoto, Kazuto Nishio, Masatoshi Kudo

Article2023

Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis

Delilah Hendriks, Jos F. Brouwers, Karien M. Hamer, Maarten H. Geurts, Léa Luciana, Simone Massalini, Carmen López‐Iglesias, Peter J. Peters, Maria J. Rodríguez Colman, Susana M. Chuva de Sousa Lopes, Benedetta Artegiani, Hans Clevers

Article2025

Correspondence to editorial on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”

Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo

Chapter in a book2014

Molecular and Metabolic Cues of the Key-Lock Paradigm Dictating Immunogenic Cell Death

Jonathan M. Pitt, Marie Vétizou, Oliver Kepp, Guido Guido Kroemer, Laurence Zitvogel

Article2025

Correspondence to letter to the editor on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”

Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo